ArticleBiofilm2023
Article in Biofilm, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review.The Journal of infectious diseases · 2024Pooled it
- The vaginal microbiome in pregnancy and preterm birth: mechanisms, disparities, and therapeutic opportunities.NPJ biofilms and microbiomes · 2026Review
- Phage therapy for treatment of bacterial vaginosis.Archives of microbiology · 2026Review
- Natural Molecules, Nutraceuticals, and Engineered Nanosystems: A Comprehensive Strategy for CombatingMicroorganisms · 2025Review
- Endolysin selectively kills Gardnerella ex vivo in vaginal samples from women with bacterial vaginosis.NPJ biofilms and microbiomes · 2025Article
- Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ biofilms and microbiomes · 2025Review
- Bacterial vaginosis.Nature reviews. Disease primers · 2025Review
- Article
- Leveraging the microbiome to combat antibiotic resistant gynecological infections.npj antimicrobials and resistance · 2025Review
- Sub-optimal menstrual materials and vaginal microbiome disruption in women relying on sex for livelihood.Frontiers in cellular and infection microbiology · 2025Article
- Eurobiofilms 2022: A translational perspective of biofilm-related persistent infections.Biofilm · 2024Article
- The human vaginal microbiota: from clinical medicine to models to mechanisms.Current opinion in microbiology · 2024Review
- Prevotella and Gardnerella Are Associated With Treatment Failure Following First-line Antibiotics for Bacterial Vaginosis.The Journal of infectious diseases · 2023Article
- Advances in bacteriophage-mediated strategies for combating polymicrobial biofilms.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial vaginosis (BV) affects approximately 26% of women of childbearing age globally, presenting with 3-5 times increased risk of miscarriage and two-fold risk of pre-term birth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.